Skip to main content
Caplight Logo









Obsidian Therapeutics

Obsidian Therapeutics

Public
Cambridge, MassachusettsBiotechhttps://obsidiantx.com/

Obsidian Therapeutics is now publicly traded

The data on this page reflects Obsidian Therapeutics's private-market history up to the point it went public, including its funding rounds, valuation, and investors.

Last Round

Private Equity

Apr 14, 2026

Est. Valuation at Exit

$763.5M

Total Funding Raised

$675M

Company Overview

Obsidian Therapeutics is a biotechnology company that develops engineered cell and gene therapies for cancer treatment using a proprietary protein-regulation platform.

Sector

Biotech

Verticals

HealthTech, Life Sciences, Oncology

AI Layer

Non-AI

Keywords

tumor-infiltrating lymphocyteTIL therapycell therapysolid tumor treatmentengineered cell therapyprotein expression regulationbiotechclinical-stage biotechimmunotherapymelanoma treatmentdrug discoveryprecision medicineclinical trialsnext-gen cell therapy

Obsidian Therapeutics Comparables

Compare Obsidian Therapeutics with similar companies based on industry and business-model similarity.

Obsidian Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Turnstone Biologics
83%
Iovance Biotherapeutics
79%
Intima Bioscience
77%

Obsidian Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Private EquityApr 14, 2026
Series CApr 3, 2024
Series BSep 9, 2021
Series ADec 6, 2017

Key People

Founding team and executive leadership

Madan Jagasia

Chief Executive Officer

Executive Team

Obsidian Therapeutics Investors

Notable investors and investment history

Obsidian Therapeutics investors
InvestorRounds
Redmile GroupPrivate Equity
Soleus CapitalSeries B
Surveyor CapitalSeries C, Series B
Janus Henderson GroupSeries C, Private Equity
Balyasny Asset Management L.P.Private Equity
RA Capital ManagementSeries C, Series B, Private Equity
TCG CrossoverSeries C, Private Equity, Series B

Recent news

Latest coverage and updates

  • attends_eventOct 2, 2026

    Obsidian Therapeutics, Inc. plans to present updated amsoki-cel data at the SITC 2026 Annual Meeting

  • goes_publicAug 5, 2026

    Obsidian Therapeutics, Inc. went public on Aug 4th '26.

  • receives_financingAug 5, 2026

    Obsidian Therapeutics, Inc. received financing of $2.1M on Mar 1st '24.

Obsidian Therapeutics Filings

Explore SEC and related filing metadata, where available.

Obsidian Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range108
Year Founded2015
Last FundingApr 14, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?